News
Lilly trumpeted positive topline results from ACHIEVE-1 (NCT05971940) showing orforglipron to have met the trial’s primary endpoint of superior A1C reduction vs. placebo at 40 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback